These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 8627604)

  • 1. Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons.
    Kalindjian SB; Buck IM; Davies JM; Dunstone DJ; Hudson ML; Low CM; McDonald IM; Pether MJ; Steel KI; Tozer MJ; Vinter JG
    J Med Chem; 1996 Apr; 39(9):1806-15. PubMed ID: 8627604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the affinity and selectivity of a nonpeptide series of cholecystokinin-B/gastrin receptor antagonists based on the dibenzobicyclo[2.2.2]octane skeleton.
    Kalindjian SB; Buck IM; Cushnir JR; Dunstone DJ; Hudson ML; Low CM; McDonald IM; Pether MJ; Steel KI; Tozer MJ
    J Med Chem; 1995 Oct; 38(21):4294-302. PubMed ID: 7473557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new class of non-peptidic cholecystokinin-B/gastrin receptor antagonists based on dibenzobicyclo[2.2.2]octane.
    Kalindjian SB; Bodkin MJ; Buck IM; Dunstone DJ; Low CM; McDonald IM; Pether MJ; Steel KI
    J Med Chem; 1994 Oct; 37(22):3671-3. PubMed ID: 7966125
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists.
    Buck IM; Black JW; Cooke T; Dunstone DJ; Gaffen JD; Griffin EP; Harper EA; Hull RA; Kalindjian SB; Lilley EJ; Linney ID; Low CM; McDonald IM; Pether MJ; Roberts SP; Shankley NP; Shaxted ME; Steel KI; Sykes DA; Tozer MJ; Watt GF; Walker MK; Wright L; Wright PT
    J Med Chem; 2005 Nov; 48(22):6803-12. PubMed ID: 16250639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat.
    Pendley CE; Fitzpatrick LR; Capolino AJ; Davis MA; Esterline NJ; Jakubowska A; Bertrand P; Guyon C; Dubroeucq MC; Martin GE
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1015-22. PubMed ID: 7791071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
    Martín-Martínez M; Bartolomé-Nebreda JM; Gómez-Monterrey I; González-Muñiz R; García-López MT; Ballaz S; Barber A; Fortuño A; Del Río J; Herranz R
    J Med Chem; 1997 Oct; 40(21):3402-7. PubMed ID: 9341915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists.
    Beinborn M; Lee YM; McBride EW; Quinn SM; Kopin AS
    Nature; 1993 Mar; 362(6418):348-50. PubMed ID: 8455720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
    Escherich A; Lutz J; Escrieut C; Fourmy D; van Neuren AS; Müller G; Schafferhans A; Klebe G; Moroder L
    Biopolymers; 2000-2001; 56(2):55-76. PubMed ID: 11592053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.
    McDonald IM; Black JW; Buck IM; Dunstone DJ; Griffin EP; Harper EA; Hull RA; Kalindjian SB; Lilley EJ; Linney ID; Pether MJ; Roberts SP; Shaxted ME; Spencer J; Steel KI; Sykes DA; Walker MK; Watt GF; Wright L; Wright PT; Xun W
    J Med Chem; 2007 Jun; 50(13):3101-12. PubMed ID: 17536796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells.
    Bellier B; McCort-Tranchepain I; Ducos B; Danascimento S; Meudal H; Noble F; Garbay C; Roques BP
    J Med Chem; 1997 Nov; 40(24):3947-56. PubMed ID: 9397175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of a new serine derivative cholecystokinin receptor antagonist TP-680 on pancreatic, biliary and gastric function.
    Tachibana I; Kanagawa K; Yamamoto Y; Otsuki M
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1404-12. PubMed ID: 8968365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog.
    Fossa AA; DePasquale MJ; Morrone J; Zorn SH; Bryce D; Lowe JA; McLean S
    J Pharmacol Exp Ther; 1997 Apr; 281(1):180-7. PubMed ID: 9103496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
    Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzotriazonine as a new core structure for the design of CCK-receptor antagonists.
    Escherich A; Escrieut C; Fourmy D; Moroder L
    J Pept Sci; 1999 Mar; 5(3):155-8. PubMed ID: 10323559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformationally constrained CCK8 analogues obtained from a rationally designed peptide library as ligands for cholecystokinin type B receptor.
    De Luca S; Saviano M; Della Moglie R; Digilio G; Bracco C; Aloj L; Tarallo L; Pedone C; Morelli G
    ChemMedChem; 2006 Sep; 1(9):997-1006. PubMed ID: 16915602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.
    Allison BD; Phuong VK; McAtee LC; Rosen M; Morton M; Prendergast C; Barrett T; Lagaud G; Freedman J; Li L; Wu X; Venkatesan H; Pippel M; Woods C; Rizzolio MC; Hack M; Hoey K; Deng X; King C; Shankley NP; Rabinowitz MH
    J Med Chem; 2006 Oct; 49(21):6371-90. PubMed ID: 17034143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
    Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
    J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic secretory response to feeding in the calf: CCK-A receptors, but not CCK-B/gastrin receptors are involved.
    Le Dréan G; Le Huërou-Luron I; Gestin M; Romé V; Bernard C; Chayvialle JA; Fourmy D; Guilloteau P
    Can J Physiol Pharmacol; 2000 Oct; 78(10):813-9. PubMed ID: 11077982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.